MEDICAL TIPS

AZIBEST TABLETS *Issue III, No. 12, 2023*

The effect of 48-weeks Azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease

Bowen DM et al; Int. Immunopharmacol. 2023; 116: 109756

- Azithromycin was evaluated for treating HIV-associated chronic lung disease (CLD) in children and adolescents due to its immunomodulatory and anti-microbial properties.
- Patients (aged 6-19 years) were randomized to receive once-weekly oral azithromycin or placebo for 48 weeks.
- Azithromycin treatment reduced plasma levels of C-reactive protein (CRP), E-Selectin and Matrix metalloproteinase 10 (MMP-10).
- Treatment effects were reversible following cessation of treatment, which indicates that these effects are due to the action of azithromycin.

Azithromycin may be useful for treating HIV-associated chronic lung disease.

❖❖❖❖❖